Thymosin Alpha-1

What is thymosin alpha-1?

Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide that helps regulate the immune system. It was first isolated in the 1970s from thymosin fraction 5, a calf thymus extract studied for its effects on immunity, by the laboratory of Allan Goldstein. Later work showed that the peptides purified from that extract were not true thymic hormones in the classic sense, but they did have real biological activity.¹

A synthetic version, thymalfasin, was developed under the brand name Zadaxin. It is approved in more than 30 countries, mainly in Asia, Latin America and parts of Europe and the Middle East, chiefly for chronic hepatitis B and as an add-on in hepatitis C. It is not approved in the United States.

In US telehealth and longevity clinics, thymosin alpha-1 is promoted for immune support, recovery from chronic infections, long COVID, and as an anti-aging immune booster. It has a far larger clinical trial record than most peptides sold this way, but that record is mostly in specific diseases, not in healthy people.

How thymosin alpha-1 works

Your immune system has two broad modes. One focuses on viruses and abnormal cells, led by T cells and natural killer cells. Thymosin alpha-1 nudges the immune system toward that mode. It helps immature T cells mature, makes antigen-presenting cells better at showing threats to T cells, and supports the activity of natural killer cells. It is an immune modulator rather than a direct antiviral.

Researchers have long grouped it with other "thymomimetic" agents that may boost Th1-type responses and delayed-type hypersensitivity, the arm of immunity most relevant to viral infections and tumors.³ It is one of several signals, along with interleukins and zinc-thymulin, that the thymus uses to support T-cell development.⁴

In more precise terms, Tα1 is an acetylated, highly charged peptide that is intrinsically unstructured in water and adopts a defined structure only under certain conditions, such as in some solvents or when bound to partner proteins.⁶ It acts in part through Toll-like receptor signaling on dendritic cells, promoting their maturation and the production of cytokines such as interleukin-2 and interferon-gamma. After subcutaneous injection it peaks in the blood within about two hours, has a serum half-life of about two hours, and returns to baseline within a day.²

What the research shows on thymosin alpha-1

The hepatitis data are the oldest. A 2001 review summarized trials in about 195 patients with hepatitis B and 162 with hepatitis C. In one randomized hepatitis B trial, viral DNA cleared in about 41% of patients after six months of treatment, compared with 9% of untreated controls. In hepatitis C, Tα1 alone did not beat placebo, but combined with interferon it improved liver enzyme normalization and viral clearance in two trials. The authors called the results mixed.² Modern direct-acting antivirals have since transformed hepatitis treatment, so these older results matter less now.

Sepsis is the most active area. A 2025 meta-analysis of 11 randomized trials with about 1,900 patients found lower 28-day mortality with Tα1 overall. However, when the analysis was limited to high-quality or multicenter trials, the benefit was no longer statistically significant, and the authors judged the total sample size inadequate. Possible benefit was concentrated in subgroups such as patients with cancer.⁷

Aging and vaccine response are newer interests. A 2025 review reported that preclinical and clinical studies suggest Tα1 can improve vaccine responses in older adults and counter aspects of immune aging, while stressing that long-term efficacy and safety in older people still need confirmation.⁸ Laboratory work has also tested Tα1, alone and with other agents, for reversing thymic shrinkage in aged, stressed mice.⁴

Some research is still at the cell-culture stage. In airway cells from people with cystic fibrosis, Tα1 reduced inflammation and improved processing of the defective CFTR protein, but this has not been shown in patients.⁵

Studied for: Chronic hepatitis B and C, Immune modulation, Vaccine adjuvant research, Sepsis research.

Thymosin Alpha-1 reference data

Thymosin Alpha-1 dosage in published research

Open this in the dosage calculator ↗

How thymosin alpha-1 is used in practice

Where it is approved, thymalfasin is given by subcutaneous injection, typically twice weekly for six to twelve months in hepatitis B. Trials commonly used 1.6 mg per dose.² In China it is also widely used in intensive care and as an add-on in cancer treatment.

In the US, thymosin alpha-1 became a popular compounded peptide through functional medicine and telehealth clinics. The FDA later placed it in Category 2 of its review of bulk substances for compounding, which restricts compounding pharmacies from using it. Much current supply comes from research-chemical vendors instead, with the familiar problems of uncertain purity, sterility and dose. Some patients import branded Zadaxin from abroad.

Thymosin alpha-1 risks and side effects

Across decades of trials, thymosin alpha-1 has been well tolerated. Most studies reported little beyond local irritation at the injection site.² Other reported effects include mild redness, transient fatigue and flu-like symptoms.

Because it is meant to enhance immune activity, it may work against immunosuppressive drugs and is generally avoided in organ transplant recipients. People with autoimmune disease should be cautious. There is little safety data in pregnancy or breastfeeding.

The bigger risks in the US come from the supply chain. A peptide made by an unregulated supplier may contain the wrong amount, synthesis byproducts, endotoxin or bacterial contamination. Using it in place of proven treatment for a serious infection or cancer is a further risk.

Reported side effects

Alternatives to thymosin alpha-1

For chronic hepatitis B, approved antivirals such as tenofovir and entecavir suppress the virus in most patients. Hepatitis C is now curable in most people with direct-acting antivirals such as sofosbuvir-velpatasvir or glecaprevir-pibrentasvir.

For sepsis, standard care remains early antibiotics, fluids, source control and organ support. For general immune resilience in older adults, vaccination against influenza, pneumococcus, shingles, RSV and COVID-19 has much stronger evidence than any peptide. Other thymic products, such as Thymalin and Thymogen, have weaker evidence than thymosin alpha-1.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?